MedTrace Logo

Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)

NCT00660647 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2015-11-24

No results posted yet for this study

Summary

Optimized treatment algorithm in early rheumatoid arthritis:

Methotrexate and intra-articular glucocorticosteroid plus adalimumab or placebo in the treatment of early rheumatoid arthritis.

A Randomised, double-blind and placebo-controlled, two arms, parallel group study of the additive effect of adalimumab concerning inflammatory control and inhibition of erosive development.

Optimized Treatment Algorithms for Patients with Early RA

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

Adalimumab

Adalimumab injection 0.8 ml (40 mg) s.c. every second week in up to 2 years

DRUG

Placebo

Saline injection 0.9%, 0.8 ml s.c. every second week up to 2 years

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Meda Pharmaceuticals

    collaborator INDUSTRY

  • Aarhus University Hospital

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Kristian Stengaard-Pedersen, Professor · Aarhus University/Aarhus University Hospital

  • Kim Hørslev-Petersen, Professor · King Christian X's Rheumatism Hospital, Graasten, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00660647 on ClinicalTrials.gov